Essential Partners’s FibroBiologics FBLG Stock Holding History

Essential Partners’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1	Closed	-$7	–	2802
2025 Q2	$7	Buy	+1	New	+$18	﹤0.01%	2265

Other funds holding FBLG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return

GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Essential Partners's FBLG Position: Q3 2025 in Review

Essential Partners sold out of FibroBiologics (FBLG) in Q3 2025, closing a stake of 1 share — an estimated $7 sold.

Essential Partners first reported a position in FBLG in Q2 2025 and held it in 1 quarter. The position peaked at $7 in Q2 2025. 52 funds tracked by Wall St. Rank hold FBLG as of Q3 2025.

Essential Partners reported no remaining FibroBiologics position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 1 FibroBiologics share in Q3 2025, an estimated $7.
Essential Partners first reported a position in FibroBiologics in Q2 2025 and held it in 1 quarter.
Essential Partners's FibroBiologics position peaked at $7 in Q2 2025.
52 funds tracked by Wall St. Rank held FibroBiologics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.